Merrimack: Clinical Trial Update (Merrimack) - Jul 18, 2015 - “Adverse events reported for MM-111 in combination with anti-cancer therapies were similar to adverse events reported for the standard of care combinations; clinical activity was observed”; “Increased HER2 expression correlated with longer PFS across all patients, supporting the mechanisms of action of both trastuzumab and MM-111”; “The sensitivity and specificity of the assays developed to measure biomarkers in this Phase 1 study supports use of the assays for the analysis of samples from an ongoing randomized Phase 2 study of MM-111 in HER2+ gastro-esophageal cancer”; “Biomarker analyses of archived and newly acquired biopsy samples will be performed in the Phase 2 study to provide further insight for the role of HER2, HER3, and HRG in the response of HER2+ cancer to MM-111-containing therapy”
P1 data • Oncology
|